Market News / Story
Neurogene is a new Overweight at J.P. Morgan on Rett syndrome therapy
Seeking Alpha ·
Seeking Alpha reports: J.P. Morgan has initiated coverage of gene therapy developer Neurogene with an Overweight recommendation, highlighting its lead program NGN-401 targeting a rare neurodevelopmental disorder known as Rett syndrome. Analyst Priyanka Grover’s bullish view came at a time when shares of the New York-based biotech had lost more than 17% since the company reported positive data from a Phase 1/2 trial of NGN-401 in females with Rett syndrome. Noting that Neurogene has posted…